文献速递细胞病理与分子病理神经与头颈病理

HPV相关头颈鳞癌细胞学标本中p16免疫组化异质性与RNA原位杂交敏感性

Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma.
PubMed 文献 · Cancer Cytopathol · 2019-09-11

本研究在97例经DNA或RNA原位杂交或PCR确认HPV状态的转移性HPV相关头颈鳞癌细针穿刺细胞块中评估p16免疫组化,并對38例PCR阳性病例行RNA原位杂交。p16阳性率93%但表达异质,RNA原位杂交在PCR阳性病例中阳性率97%,提示任何p16阳性应行确证性HPV检测,RNA原位杂交或可作细胞学标本一线HPV检测。

要点

  • p16在转移性HPV-HNSCC细胞块中表达异质,任何阳性均应确证HPV。
  • RNA原位杂交在PCR阳性细胞学标本中显示高敏感性(97%)。
  • 实验室可考虑将RNA原位杂交作为细胞学标本一线HPV检测。

核心结论

  • p16在转移性HPV-HNSCC细胞块中表达异质,任何p16阳性均应行确证性HPV检测。
  • RNA原位杂交在细胞学标本中显示高敏感性,或可作一线HPV检测。

研究设计与样本

  • 对97例转移性HPV-HNSCC细针穿刺细胞块行p16免疫组化,HPV状态经DNA或RNA原位杂交或PCR确认。
  • 记录肿瘤细胞量(<100、100-500、>500个细胞)与质量(细胞簇、坏死),评估p16染色强度与范围。
  • 对38例PCR阳性病例行RNA原位杂交。

主要发现

  • p16免疫组化在97例中90例(93%)阳性,表现异质。
  • 69例p16中至强染色,其中37例(38%)≥70%肿瘤细胞阳性。
  • 21例(22%)弱染色,7例(7%)阴性。
  • 60例弱和/或缺失或<70%细胞染色病例中,30例(50%)肿瘤细胞<100个,12例(20%)缺乏细胞簇,19例(32%)广泛坏死。
  • RNA原位杂交在38例PCR阳性病例中37例(97%)阳性。

关键数值与推荐

  • p16染色范围分为1%-9%、10%-69%、≥70%。
  • 肿瘤细胞量分为<100、100-500、>500个细胞。
  • RNA原位杂交阳性判定:37/38例PCR阳性病例阳性(97%)。

临床怎么用

  • 细胞块p16阳性(任何程度)应行确证性HPV检测。
  • 可考虑将RNA原位杂交作为细胞学标本一线HPV检测。
  • 评估p16时需注意细胞量少、缺乏细胞簇和广泛坏死可能影响判读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Many patients with human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HPV-HNSCC) initially present with cervical lymph node metastases. Although p16 immunohistochemistry (IHC) is the most commonly used surrogate marker for HPV, however criteria in cytologic material are not well established. The objective of this study was to better characterize p16 IHC in cell blocks of metastatic HPV-HNSCC, and to evaluate the performance of HPV RNA in situ hybridization (RNA ISH). METHODS: p16 IHC was performed on cell blocks from 97 metastatic HPV-HNSCC fine-needle aspiration specimens with HPV status confirmed by DNA or RNA ISH or polymerase chain reaction (PCR). Tumor cellularity (<100 cells, 100-500 cells, and >500 cells) and quality (presence of cell clusters, necrosis) were recorded. p16 staining intensity and extent (1%-9%, 10%-69%, and ≥70%) were scored. In addition, RNA ISH was performed on 38 PCR-positive cases. RESULTS: p16 IHC was positive in 90 of 97 cases (93%), demonstrating variable patterns. p16 staining was found to be moderate to strong in 69 cases, with 37 cases (38%) demonstrating positivity in ≥70% of tumor cells. Weak staining occurred in 21 cases (22%) and 7 cases (7%) were negative. Of the 60 cases with weak and/or absent expression or staining in <70% of cells, 30 cases (50%) had <100 tumor cells, 12 (20%) lacked cell clusters, and 19 cases (32%) had extensive necrosis. RNA ISH was positive in 37 of 38 cases (97%) that were HPV positive by PCR. CONCLUSIONS: p16 is heterogeneous in cell blocks of metastatic HPV-HNSCC, suggesting that any p16 positivity should prompt confirmatory HPV studies. RNA ISH appears to demonstrate high sensitivity, and laboratories even may consider using RNA ISH as a first-line HPV test in cytologic specimens.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Wong KS, Krane JF, Jo VY, et al. Heterogeneity of p16 immunohistochemistry and increased sensitivity of RNA in situ hybridization in cytology specimens of HPV-related head and neck squamous cell carcinoma. Cancer Cytopathol. 2019. PMID: 31509355. doi:10.1002/cncy.22178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。